Ipsen: Kayfanda approved for Alagille syndrome

(CercleFinance.com) - Ipsen announces the European Commission's approval, under exceptional circumstances, of Kayfanda for the treatment of cholestatic pruritus associated with Alagille Syndrome (AS), a rare liver disease, in patients aged six months or older.


Kayfanda's active ingredient, odévixibat, blocks the ileal bile acid transporter (IBAT), thereby reducing the serum concentration of bile acids in the liver", explains the pharmaceutical company.

This marketing authorisation in the EU is based on data from ASSERT, the only Phase III trial completed in patients with GAS. The drug is also being studied in a Phase III trial, BOLD, in biliary atresia.


Copyright (c) 2024 CercleFinance.com. All rights reserved.